Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
Phase 1
- Conditions
- Cutaneous T-Cell Lymphoma
- Registration Number
- NCT00779896
- Lead Sponsor
- McGill University
- Brief Summary
This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- Patients with Stage I-IIA CTCL must be at least 18 years of age with a skin biopsy prior to enrolment confirming the diagnosis of mycosis fungoides.
Exclusion Criteria
- Patients with Stage >IIA CTCL at the time of enrolment
- Women who are pregnant or planning to get pregnant, or unable/unwilling to use adequate contraception
- Patients who were treated with topical retinoid therapy in the past 3 months
- Patients who received any systemic CTCL therapy or systemic corticosteroid therapy within 30 days of the study start date
- Patients who were treated with systemic isotretinoin or bexarotene within 3 months prior to the study start date, systemic acitretin within 2 years prior to study start date
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Partial response (PR) is defined as some improvement (25%-50%);significant evidence of disease remains or disease has not changed from baseline condition (<25%);no new clinically abnormal(>1.5 cm)lymph nodes,<25% progression of existence
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
McGill University
🇨🇦Montreal, Quebec, Canada